Surgical management of tuberculous epididymo-orchitis: a retrospective study of 81 cases with long-term follow-up

Yin Huang1,2†, Bo Chen1†, Dehong Cao1†, Zeyu Chen1, Jin Li1, Jianbing Guo1, Qiang Dong1, Qiang Wei1* and Liangren Liu1*

Abstract

Background: Nowadays, most studies of tuberculous epididymo-orchitis (TBEO) are case reports or small sample cohort series. Our study is aimed to present the largest series of TBEO with our management experiences and long-term follow-up outcomes.

Methods: Patients diagnosed with TBEO after surgical procedures at Department of Urology, West China Hospital from 2008 to 2019 were included. All clinical features, auxiliary examination results, treatment and histopathological findings were extracted if available.

Results: Eighty-one patients (mean age 50.77 ± 16.1 years) were included. Scrotal swelling (N = 47, 58.0%) and pain (N = 29, 35.8%) were the most common presenting complaint. Pyuria and microscopic hematuria were observed in twenty-two (27.2%) and eight patients (9.9%), respectively. Urine acid fast bacilli cultures were available in 16 patients and all were negative. The mean duration between the onset of symptoms and the definite diagnosis was 6.42 ± 7.0 months. TBEO was considered in 30 (37.0%), tumors in 28 (34.6%) and nonspecific bacterial epididymo-orchitis in 23 (28.4%) patients. All patients received triple therapy of chemotherapy-surgery-pharmacotherapy and definite diagnosis was confirmed through histopathology of surgical specimens. Fifty-five patients were followed up regularly (mean follow-up 82.35 ± 36.6 months). One patient (1.2%) died from liver cirrhosis and no recurrence was observed. Postoperative complications included erectile dysfunction in 4 patients (4.9%), premature ejaculation in 5 patients (6.2%) and sterility in 7 patients (8.6%).

Conclusions: We recommend patients with advanced TBEO to receive triple therapy of chemotherapy-surgery-pharmacotherapy. Physicians should pay more attention to patients’ sexual function and fertility during follow up after treatment completed.

Keywords: Tuberculosis, Epididymo-orchitis, Chemotherapy-surgery-pharmacotherapy, Follow up, Sexual function, Fertility

Background

According to the 2019 World Health Organization global tuberculosis (TB) report, about 10 million (range, 9.0–11.1 million) new cases of TB were reported worldwide in 2018. There were an estimated 1.2 million TB deaths among HIV-negative people and an additional 251,000 deaths among HIV positive people in 2018 [1]. TB can...
affect people of both sexes in all age groups but the highest burden is in men (aged ≥ 15 years), who accounted for 57% of all TB cases, while women and children (aged <15 years) accounted for 32% and 11%, respectively. China is the second highest TB-burden country after India, accounting for 9% of global TB cases in 2018 [1]. In addition to lymphatic involvement, urogenital TB is the most common manifestation of extrapulmonary TB and is more frequent in middle-aged men, which accounts for 33.7–45.5% of the extrapulmonary TB worldwide [2]. Compared with renal TB, male genital TB is a rare subtype of the urogenital TB, which can be classified as TB epididymitis, TB orchitis, TB of the prostate, TB of the seminal vesicles, and TB of the penis [2, 3].

Since the lack of preoperative diagnostic methods with high sensitivity and specificity, tuberculous epididymo-orchitis (TBOE) with nonspecific clinical signs is often misdiagnosed with bacterial infection or tumor [4]. Standard anti-tuberculosis chemotherapy is the first-line therapy for TBOE. However, surgical intervention may be unavoidable in cases of hard to diagnose, or poorly responding to chemotherapy [5–7]. Patients with TBOE received regular anti-tuberculosis chemotherapy plus surgery intervention are seldom to recur [4, 8]. Nowadays, the majority of studies of TBOE are case reports or small sample cohort series including less than 50 cases. Furthermore, long-term follow-up data after treatment are deficient [4–6, 8]. Therefore, our study is aimed to present our experiences on the clinicopathological characteristics, management and 11-year follow-up outcomes of TBOE at a large medical center in west China.

Methods

Setting and study design

From January 2008 to May 2019, patients diagnosed with TBOE after surgical procedures at Department of Urology, West China Hospital were included in our retrospective observational study. All clinical features (symptoms, physical signs, duration of disease, past medical history, comorbidities and organ involvement), auxiliary examination results (hemogram, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), urinalysis, blood biochemistry, tumor markers, urine culture, ultrasonography and radiology), treatment (drug therapy and surgery) and histopathological findings (microscopy, Ziehl–Neelsen acid fast stain and polymerase chain reaction (PCR)) were retrieved from medical records if available. Patients who only received drug therapy without surgery were excluded.

Diagnosis

TBOE was definitely diagnosed in the presence of clinical findings combined with one of the following criteria: (1) Positivity of acid fast bacilli (AFB) in urine. (2) Positive urine culture for M. tuberculosis. (3) Positivity of PCR for M. tuberculosis in urine. (4) Typical granulomatous inflammation with caseous necrosis in microscopy plus any positivity of Ziehl–Neelsen acid fast stain or PCR for M. tuberculosis in any relevant tissue specimen [9]. In our institution, histopathological evidence of TBOE was only obtained from postoperative histopathological findings of surgical specimens, no preoperative histopathological examination (e.g. fine-needle aspiration cytology (FNAC)) was performed. According to the criteria of our institution: ESR > 20 mm/1 h, CRP > 5 mg/L, serum beta-human chorionic gonadotropin (β-HCG) ≥ 3.81 mIU/ml, serum alpha-fetoprotein (AFP) ≥ 8 ng/ml and serum lactate dehydrogenase (LDH) ≥ 220 U/L were considered to be elevated.

Treatment and follow up

Surgical indications for patients with TBOE in our center including: (1) Regular anti-tuberculosis pharmacotherapy for 1–2 months was completed but tuberculous lesions were still not controlled. (2) TBOE was diagnosed in advanced stage with widely spread of M. tuberculosis. (3) Tuberculous complications including hydrocele, abscess, sinus or fistula were observed. (4) Clinical diagnosis of scrotal tumors was suspected. (5) Clinical diagnosis was nonspecific bacterial epididymo-orchitis but the efficacy of antibiotic treatment was limited. Patients with clinical diagnosis of TBOE received anti-tuberculosis chemotherapy for 2–4 weeks before surgery. Surgical procedure (orchiectomy, epididymectomy or epididymo-orchidectomy) and postoperative anti-tuberculosis therapy with 4 drugs (rifampicin, isoniazid, ethambutol and pyrazinamide) for 6–12 months were performed in all patients. After completion of the therapy, patients were followed up for symptoms, physical examination, scrotal ultrasound, sexual function and fertility until June, 2020.

Statistical analysis

The data were analyzed by the IBM SPSS Statistics (version 25). Continuous variables were expressed as mean ± standard deviation (SD) or median with interquartile range (IQR). P value < 0.05 was considered as statistically significant.

Results

Clinical characteristics

During the 11 years period of the study, a total of 98 cases were recorded as TBOE. After exclusion of those not meeting the diagnostic criteria (N = 11), repeating records (N = 2) and patients who did not undergo surgery (N = 4), 81 separate patients with TBOE were included in our study. Clinical characteristics including symptoms,
physical examination, urinalysis, laboratory findings and history of TB of 81 patients are shown in Table 1.

The average age of the patients was 50.77 ± 16.1 years (range, 13–90 years). Scrotal swelling (N = 47, 58.0%) was the most common presenting complaint, followed by scrotal pain (N = 29, 35.8%). Unilateral and bilateral scrotal mass were detected through physical examination in 43 (53.1%) and 4 (4.9%) patients, respectively. The most positive findings of urinalysis were pyuria (N = 22, 27.2%) and microscopic hematuria (N = 8, 9.9%). AFB culture results were available in only 16 patients and all were negative. The duration between the onset of symptoms and the definite diagnosis varied from 0.3 to 36 months, with an average duration of 6.42 ± 7.0 months. Furthermore, TB history of other organs was reported in ten patients (12.3%). Besides, fifteen patients (18.5%) were diagnosed with TBEO in other medical centers before registered in our hospital and had received regular anti-tuberculosis pharmacotherapy for 1–12 months, but the scrotal tuberculosis lesions of these patients were not controlled effectively.

Abnormal rates of imaging findings in 81 patients are shown in Table 2. Scrotal ultrasound detected the signs of epididymo-orchitis in 30 of 39 patients. Forty-one patients received computed tomography (CT) scan and infectious disease was observed in 36 patients. Magnetic resonance imaging (MRI) was performed in 2 patients and both found an abnormality. Chest radiological evidence of pulmonary infection was found in 43 of 81 patients, and 6 patients (7.4%) had evidence of active pulmonary TB. In addition, ten cases (12.3%) of hydrocele and four cases (4.9%) of varicocele were confirmed by scrotal imaging.

**Clinical diagnosis and treatment**

Before surgery, thirty patients (37.0%) were clinically diagnosed with TBEO, while 28 patients (34.6%) were diagnosed with tumors. Twenty-three patients (28.4%) were preoperatively diagnosed with nonspecific bacterial epididymo-orchitis but routine antibiotic treatment was noneffective (Table 3). Surgical procedure was performed for all patients. Thirty patients with clinical diagnosis of TBEO received preoperative antituberculosis chemotherapy for 2–4 week. Orchietomy, epididymectomy and epididymo-orchidectomy were performed in two (2.5%), twenty-seven (33.3%) and fifty-two (64.2%) patients, respectively. Seventy-five patients (92.6%) received unilateral orchietomy or epididymectomy. Bilateral surgical procedure was performed in 6 patients (7.4%) (Table 3). Scrotal masses were found in 43 patients (53.1%) in surgery, with the mean diameter of 3.18 ± 1.6 cm (range, 0.2–7.0 cm).

| Table 1 | Clinical characteristics of 81 patients |
|----------|--------------------------------------|
| **Characteristics** | **No. Pts/total (%)** |
| Ages (years) | |
| < 60 | 62/81 (76.5) |
| ≥ 60 | 19/81 (23.5) |
| Symptoms | |
| Scrotal swelling | 47/81 (58.0) |
| Scrotal pain | 29/81 (35.8) |
| Fever | 6/81 (7.4) |
| Night sweats | 1/81 (1.2) |
| Weight loss | 11/81 (13.6) |
| Frequency / urgency | 2/81 (2.5) |
| Dysuria | 3/81 (3.7) |
| Physical examination | |
| Left scrotal mass | 16/81 (19.8) |
| Right scrotal mass | 27/81 (33.3) |
| Bilateral scrotal mass | 4/81 (4.9) |
| Abscess | 2/81 (2.5) |
| Sinus | 1/81 (1.2) |
| Urinalysis | |
| Pyuria | 22/81 (27.2) |
| Microscopic hematuria | 8/81 (9.9) |
| Positive urine AFB culture | 0/16 (0) |
| Laboratory findings | |
| Increased ESR | 7/14 (50.0) |
| Increased CRP | 5/8 (62.5) |
| Increased WBC | 4/81 (4.9) |
| Increased serum AFP | 3/30 (10.0) |
| Increased serum β-HCG | 1/30 (3.3) |
| Increased serum LDH | 10/81 (12.3) |
| Anemia | 8/81 (9.9) |
| Hypoa1buminemia | 12/81 (14.8) |
| History of TB | 10/81 (12.3) |
| Lung | 8/81 (9.9) |
| Kidney | 1/81 (1.2) |
| Bone | 1/81 (1.2) |

*AFB acid fast bacilli, ESR erythrocyte sedimentation rate, CRP C-reactive protein, WBC white blood cell, AFP alpha-fetoprotein, β-HCG beta-human chorionic gonadotropin, LDH lactate dehydrogenase, TB tuberculosis*

| Table 2 | Abnormal rates of imaging findings in 81 patients |
|----------|--------------------------------------|
| **Imaging modality** | **No. Pts (total)** | **Percentage (%)** |
| Ultrasonography | 30 (39) | 76.9 |
| Computed tomography | 36 (41) | 87.8 |
| Magnetic resonance | 2 (2) | 100 |
| Chest radiography | 43 (81) | 53.1 |
Histopathological findings
Postoperative histopathology showed the typical granulomatous inflammation with amorphous caseous necrosis in all surgical specimens (Fig. 1A). At high magnification, the amorphous caseous necrosis was surrounded by granulomas containing epithelioid histiocytes, Langhans giant cells and lymphocytes (Fig. 1B). Ziehl–Neelsen acid fast stain was performed in 77 specimens and was positive in sixty-two (80.5%). PCR findings for \textit{M. tuberculosis} identification were available in 43 surgical specimens and twenty-four cases (55.8%) showed a positive result. Results of histopathological findings are shown in Table 3.

Prognosis
All patients were followed up regularly until June, 2020 except 26 patients (32.1%) due to loss of contacts. Follow-up ranged from 14 months to 11.5 years, with an average follow-up of 82.35 ± 36.6 months. During follow up, only 1 patient (1.2%) died from liver cirrhosis and no recurrence was observed. Symptoms such as fever, scrotal pain and irritative urinary symptoms were under control in 47 cases (58.0%). Urinalysis parameters and scrotal imaging were stable in 50 patients (61.7%). Postoperative complications included erectile dysfunction in 4 patients (4.9%), premature ejaculation in 5 patients (6.2%) and sterility in 7 patients (8.6%).

Discussion
Until now, \textit{M. tuberculosis} was the most frequently isolated species in humans all over the world, followed by \textit{M. bovis} [10]. However, the species \textit{M. tuberculosis} has been inaccurately used to represent the Mycobacterium tuberculosis complex (MTBC), including \textit{M. tuberculosis}, \textit{M. africanum}, \textit{M. bovis}, \textit{M. canettii} and so on [10, 11]. As one of the most virulent pathogens for humans, \textit{M. tuberculosis} has a slow replication rate, which accounts for the latent nature of the infection and its resistance to conventional antibiotics [3]. Despite the bacillus could stay dormant in the human body without any symptoms for a long time, injury of immune function may induce its reactivation [10].

Urogenital TB is the second common form of extrapulmonary TB which occurs in 15% to 20% cases of pulmonary TB with a prevalence of 400 per 100,000 population, mostly affecting middle-aged men [2, 12]. Given the high prevalence of TB worldwide, urogenital TB reflects a large burden of urogenital diseases, especially in countries with a severe epidemic situation including China. Male genital TB is a rare subtype of urogenital TB, usually occurring in men aged 30–50 years [5]. Similarly, our

### Table 3 Clinical diagnosis, treatment and histopathology characteristics of 81 patients

| Characteristics                                      | No. Pts (total) | Percentage (%) |
|------------------------------------------------------|-----------------|----------------|
| Clinical diagnosis                                   |                 |                |
| TBEO                                                 | 30 (81)         | 37.0           |
| Tumor                                                | 28 (81)         | 34.6           |
| Nonspecific bacterial epididymo-orchitis             | 23 (81)         | 28.4           |
| Surgical procedure                                   |                 |                |
| Unilateral                                           | 75 (81)         | 92.6           |
| Bilateral                                             | 6 (81)          | 7.4            |
| Orchiectomy                                          | 2 (81)          | 2.5            |
| Epididymectomy                                       | 27 (81)         | 33.3           |
| Epididymo-orchiectomy                                | 52 (81)         | 64.2           |
| Histopathology                                       |                 |                |
| Positive acid fast stain                             | 62 (77)         | 80.5           |
| Positive PCR                                          | 24 (43)         | 55.8           |
| Any of the above                                     | 81 (81)         | 100            |
| Granulomatous inflammation with caseous necrosis     | 81 (81)         | 100            |
| Isolated testicular TB                               | 23 (81)         | 28.4           |
| Isolated epididymal TB                               | 31 (81)         | 38.3           |
| Testicular and epididymal TB                         | 27 (81)         | 33.3           |

TBEO: tuberculous epididymo-orchitis, PCR: polymerase chain reaction, TB: tuberculosis

*One patient underwent bilateral orchiectomy, one patient underwent bilateral epididymectomy, and four patients underwent orchiectomy and contralateral epididymectomy.*
cohort was consisted of a wide range of ages with a mean age of 50.77 ± 16.1 years (range, 13–90 years). In our study, 10 patients (12.3%) reported a history of TB compared with 34% to 76% reported in the literature [5]. The low rate in our series was probably due to the retrospective nature of our study.

Some studies suggest that male genital TB often results from direct infection from urine, while other experts suggest that haematogenous and lymphatic spread are the most common pathways of initial infection in male genital TB [2, 5]. Muneer et al.[13] thought that TBOE is caused by direct spread from the lower urinary tract or retrograde spread of M. tuberculosis via the prostate and into the epididymis, and TB of the testis is always secondary to infection of the epididymis. However, in our study, 23 patients (28.4%) were defined as isolated testicular TB and no patients were diagnosed with prostatic TB, which probably attributed to the latent presentation and delayed diagnosis of TB. In addition, sexual transmission is thought to be possible since M. tuberculosis has been isolated form the ejaculate of men with prostatic TB [5, 13].

The onset of clinically evident TBOE is insidious, with variable clinical manifestations. Most studies found that a scrotal swelling, scrotal pain and irritative voiding symptoms are the common initial symptoms of patients with TBOE, which is similar to our findings [4, 8, 12]. On physical examination, the scrotal mass may be either painful or painless [6]. Nonspecific constitutional symptoms of TB such as fever, weight loss, fatigue and night sweats are uncommon [9, 13]. However, suspicion of concomitant TB outside the urogenital tract should arise when these constitutional symptoms are present, such as pulmonary TB [13]. Compared with other reports in the literature, the average duration between onset of the symptoms and the definite diagnosis (mean 6.42 ± 7.0 months, range 0.3–36 months) in our study was longer, probably due to the insidious and asymptomatic onset of TBOE [5, 14–16].

Urinalysis was reported abnormal in 77–90% of patients with urogenital TB [5]. Altiparmak et al.[9] reported that hematuria and pyuria were detected in 79.7% and 67.1% of patients, respectively. However, in our study, pyuria and hematuria were only observed in twenty-two (27.2%) and eight patients (9.9%), respectively. Similar to our findings, abnormal urinalysis (hematuria and pyuria) was detected in 59.6% of patients in another cohort study with 47 cases of epididymal tuberculosis [4]. This result may be because all patients in our study were isolated TBOE without renal involvement. Urine AFB culture was long considered the gold standard in diagnosis of urogenital TB. However, low sensitivity of culture was reported in the literature and the negative urine cultures do not rule out the possibility of TBOE. In addition, cultures may take several weeks to show a delayed result [5, 6, 17]. In our series, however, results of urine AFB cultures were only available in 16 patients since the retrospective nature of the study, and all were negative. On the other hand, patients might not receive the urine AFB cultures when the clinical diagnosis of tumor was considered before surgery. Given the small sample size, our results are not enough to suggest the low significance of urine AFB culture in diagnosis of TBOE.

Recent years, as a rapid test for detecting M. tuberculosis DNA and rifampicin resistance, GenXpert MTB/RIF was identified to be the better choice in diagnosing urogenital TB according to its higher sensitivity compared with urine microscopy and culture [13]. Furthermore, interferon-γ release assays (including QuantiFERON-TB Gold In-Tube and T-SPOT TB) were recommended...
to detect latent TB infection, especially for asymptomatic individuals with high risk of TB infection [13]. However, data of GenXpert MTB/RIF and interferon-γ release assays were not available in our study due to the retrospective design. In addition, some studies reported that nucleic acid amplification (NAA) tests of the urine are helpful adjunctive tools for rapid diagnosis of renal TB, with a specificity and sensitivity of 95.6% and 98.1%, respectively. But the value of NAA tests in diagnosis of male genital TB is still controversial [5, 6]. According to some reviews, FNAC can be used to diagnose TB of the external male genitals [2, 13]. In our opinion, however, FNAC should not be used for diagnosis of TBO or testicular tumor, given the risk of fistula formation and spread of \textit{M. tuberculosis} or tumor cell. Therefore, none of our patients received FNAC.

TBO in the early stages always has no specific scrotal imaging findings [5, 13]. Ultrasound of TBO can show diffusely or nodular enlarged hypoechoic lesions. Other features including scrotal wall and tunica albuginea thickening, hydrocele, varicocele and intratesticular abscesses can also be seen in scrotal ultrasound. On a contrast-enhanced CT scan, TBO can be seen as heterogeneous or annular enhancement, cavitation lesions or irregular mass (Fig. 2). Calcification may also be observed in advanced TB. However, these findings in scrotal imaging are not TB-specific and cannot be distinguished from an abscess or malignancy [2, 5, 13]. In addition, the proportion of cases with active pulmonary TB in our study (7.4%) was consistent with the literature [9, 13].

Male TBO can present as a nonspecific epididymo-orchitis and testicular mass in clinical features that is difficult to differentiate from nonspecific infectious diseases and malignancy [5]. Similarly, scrotal tumors (34.6%) and nonspecific bacterial epididymo-orchitis (28.4%) were the most common misdiagnosis in our study. Given the deficiency of preoperative diagnostic method with high sensitivity and specificity, histopathology of surgical specimens including microscopy, acid fast stain and/or PCR for \textit{M. tuberculosis} remains the gold standard for diagnosis of TBO, especially in isolated TBO without renal and prostate involvement [2, 8]. Borges et al. reported a case of TBO recently, in which a surgical intervention of right epididymo-orchidectomy through the inguinal canal was performed, given the possibility of malignant neoplasm of the epididymis [18]. As reported by a review of urogenital TB, in up to one-fifth of patients, TBO is only diagnosed after epididymo-orchidectomy and histopathological examination [13]. In our study, all definitive diagnosis of TBO was confirmed by histopathology of surgical specimens.

Most studies recommended anti-tuberculosis chemotherapy as the first-line treatment for TBO. Surgery should only be considered for patients not respond to chemotherapy and for the correction of complications [2, 5, 8]. However, the value of anti-tuberculosis chemotherapy alone for TBO is limited in our study since most patients have developed with complications (hydrocele, abscess, sinus or fistula) or been advanced stages when diagnosis of TBO was confirmed due to its latent presentation. Moreover, successful medical treatment of TB might be hampered by drug tolerance of \textit{M. tuberculosis} [19]. Recently, Goossens et al. have proposed four possible mechanisms for drug tolerance of \textit{M. tuberculosis}, including metabolic slowdown through reducing the metabolism and growth rate, metabolic shifting, cell wall thickening, and the upregulation of efflux pumps [19]. In our series, 15 patients (18.5%) had received regular anti-tuberculosis pharmacotherapy for 1–12 months in other medical centers before surgery but the scrotal tuberculosis lesions were not controlled effectively, and
tuberculous complications including hydrocele, abscess and sinus were observed in 13 patients (16.0%). In this situation, radical surgery is often unavoidable, which can be used for resection of the lesions and histopathological examination [4, 6, 13, 20]. However, it is worth noting that Bedi et al. has successfully treated a 38-year-old patient with TBOE by standard anti-tuberculous medications [14]. Besides, Abraham et al. also reported an Ecuadorian man with TBOE who was cured with 6 months of drug therapy and no surgery was required [21]. Therefore, for patients at early stages without server complications, standard anti-tuberculosis chemotherapy is still necessary to avoid surgical resection [15, 16, 22, 23].

In our study, all patients clinically diagnosed with TBOE received triple therapy of preoperative anti-tuberculosis chemotherapy for 2–4 weeks, radical surgery and postoperative anti-tuberculosis therapy with 4 drugs (rifampicin, isoniazid, ethambutol and pyrazinamide) for 6–12 months. The preoperative anti-tuberculosis chemotherapy was aimed to control the quantity of M. tuberculosis in tissues and blood to prepare for surgery, while the postoperative anti-tuberculosis drug therapy was used for eradicating the remaining M. tuberculosis to prevent recurrence. Given TB of the testis is always secondary to infection of the epididymis, epididymectomy (33.3%) and epididymo-orchidectomy (64.2%) were the main surgical procedure for TBOE in our study. But there were still two patients (2.5%) who received simple orchidectomy due to the preoperative imaging suggested that the lesion was confined in testis and no epididymal involvement was found during operation. After standard therapy was completed, all patients recovered well and no recurrence was observed during follow up except one patient died from liver cirrhosis. Postoperative complications including sexual dysfunction and sterility were respectively reported in nine (11.1%) and seven (8.6%) patients, suggesting that physicians should pay more attention to the sexual function and fertility of TBOE patients who received radical surgery during follow up.

We must acknowledge several limitations of our study. Firstly, patient data such as serum ESR, CRP and gonadal hormone levels, urine AFB cultures, PCR for M. tuberculosis, GenXpert MTB/RIF and interferon-γ release assays were not completed because of the nature of retrospective study. Secondly, the data of patients successfully treated with anti-tuberculosis drugs without surgery were not available for comparative analysis. Thirdly, our study was a single-center study without sufficient data from other medical centers, which may have resulted in a certain degree of selection bias. Finally, some patients lost to follow-up even if try to contact with their relatives and families, which may affect the accuracy of our findings.

Conclusions
Given the deficiency of diagnostic tools with high sensitivity and specificity, radical surgery followed by histopathological examination might be unavoidable for diagnosis and treatment. We recommend patients diagnosed with advanced TBOE to receive triple therapy of chemotherapy-surgery-pharmacotherapy to correct complications and minimize the risk of recurrence especially in endemic area. After triple therapy is completed, physicians should pay more attention to patients’ sexual function and fertility during follow up.

Abbreviations
TBOE: Tuberculous epididymo-orchitis; TB: Tuberculosis; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; PCR: Polymerase chain reaction; AFB: Acid fast bacilli; FNAC: Fine-needle aspiration cytology; β-HCG: Beta-human chorionic gonadotropin; AFP: Alpha-fetoprotein; LDH: Lactate dehydrogenase; SD: Standard deviation; IQR: Interquartile range; CT: Computed tomography; MRI: Magnetic resonance imaging; MTBC: Mycobacterium tuberculosis complex; NAA: Nucleic acid amplification.

Acknowledgements
Not applicable.

Authors’ contributions
YH and BC collected, analyzed clinical data and wrote the manuscript. LRL, DHC and QW designed the study, supervised the project, and revised the manuscript. DHC, JL and QD helped with patients follow-up and interpreted the clinical data. All authors read and approved the final manuscript.

Funding
The collection, analysis, and interpretation of data of this study was funded by the National Natural Science Foundation of China (Grant Number 82000721) and Program from the Department of Science and Technology of Sichuan Province (Grant Number 2020YJ0054).

Availability of data and materials
The datasets used and/or analyzed in the current study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate
This study was approved by the Ethics Committee on Biomedical Research, West China Hospital of Sichuan University. All methods were carried out in this study in accordance with relevant guidelines and regulations. Individual written informed consent for participating this study was obtained from the patients or patients’ parents or guardians.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflicts of interest.

Author details
1Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Guoxue Alley, No. 37, Chengdu 610041, Sichuan, People’s Republic of China. 2West China School of Medicine, Sichuan University, Chengdu, China.

Received: 14 December 2020   Accepted: 1 October 2021
Published online: 15 October 2021
References

1. Organization WH. Global tuberculosis report 2019. Geneva: World Health Organization. 2019. https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1. Accessed 12 June 2020.

2. Kulchavenya E, Naber K, Bjerkand Johansen TE. Urogenital Tuberculosis: Classification, Diagnosis, and Treatment. Eur Urol Suppl. 2016;5169905616300471.

3. Figueiredo AA, Lucon AM, Srougi M. Urogenital tuberculosis. Microbiol Spectr. 2017;5:1. https://doi.org/10.1128/microbiolspec.TNM7-0015-2016.

4. Man J, Cao L, Dong Z, Tian J, Wang Z, Yang L. Diagnosis and treatment of epididymal tuberculosis: a review of 47 cases. Peer J. 2020;8:e8291. https://doi.org/10.7717/peerj.8291.

5. Jacob JT, Nguyen TM, Ray SM. Male genital tuberculosis. Lancet Infect Dis. 2016;16:1399–411. https://doi.org/10.1016/S1473-3099(16)30633-8.

6. Thompson RW, Yu H, Dahl DM, Hurtado RM, Sajed DP. Case 10–2018: an 84-year-old man with painless unilateral testicular swelling N Engl J Med. 2018;378(3):1233–40. https://doi.org/10.1056/NEJMc1712224.

7. Paron NI, Borand L, Benedicto J, Kyi MM, Mahmud AM, Norazmi MN, et al. Diagnosis and management of latent tuberculosis infection in Asia: Review of current status and challenges. Int J Infect Dis. 2019;87:21–9. https://doi.org/10.1016/j.ijid.2019.07.004.

8. Suansriwan U, Larbcharoensub N, Visesvithi W, Wiratkapun C, Chalermsanyakorn P. A clinicopathologic study of tuberculosis epididymo-orchitis in Thailand. Southeast Asian J Trop Med Public Health. 2012;43(4):951–8.

9. Altintepe L, Tonbul HZ, Ozsey I, Guney I, Odabas AR, Cetinkaya R, et al. Urinary tuberculosis: ten years’ experience. Ren Fail. 2005;27(6):657–61. https://doi.org/10.1080/0886020500234857.

10. Chang A, Blackburn B, Hiseh M. Tuberculosis and parasitic infections of the genitourinary tract Campbell-Walsh urology. 11th ed. New York: Elsevier; 2016. p. 421–46.

11. Yeoboa-Manu D, de Jong BC, Gehre F. The Biology and Epidemiology of Mycobacterium africanum. Adv Exp Med Biol. 2017;1019:117–33. https://doi.org/10.1007/978-3-319-64371-7_6.

12. Gupta NP, Kumar R, Mundada OP, Anon M, Hemal AK, Dogra PN et al. Reconstructive surgery for the management of genitourinary tuberculosis: a single center experience. J Urol. 2006;175(6):2150–4. doi: https://doi.org/10.1016/s0022-5347(06)00310-7 (discussion 4).

13. Muneer A, Macrae B, Krishnamoorthy S, Zumla A. Urogenital tuberculosis — epidemiology, pathogenesis and clinical features. Nat Rev Urol. 2019.

14. Bedi N, Rahimi MNC, Menzies S, Kalsi J. Atypical testicular pain. BMJ Case Rep. 2019;12(2). https://doi.org/10.1136/bcr-2018-226697.

15. Hadadi A, Pourmand G, Mehdipour-Aghabagher B. Unilateral testicular tuberculosis: case report. Andrologia. 2012;44(1):70–2. https://doi.org/10.1111/j.1439-0272.2010.01097.x.

16. Kinnear N, Hoh I, Campillo P, Bolt J. Tuberculous epididymo-orchitis masquerading as acute scrotum. BMJ Case Rep. 2016. https://doi.org/10.1136/bcr-2015-214060.

17. Altintepe L, Tonbul HZ, Ozsey I, Guney I, Odabas AR, Cetinkaya R, et al. Urinary tuberculosis: ten years’ experience. Ren Fail. 2005;27(6):657–61. https://doi.org/10.1080/0886020500234857.

18. Borges WM, Bechara GR, de Miranda MML, de Figueiredo GB, Venturini BA, Laghi CR. Epididymis tuberculosis: case report and brief review of the literature. Urol Case Rep. 2019;26:100969. https://doi.org/10.1016/j.eucr.2019.100969.

19. Goossens SN, Sampson SL, Van Rie A. Mechanisms of Drug-Induced Tolerance in Mycobacterium tuberculosis. Clin Microbiol Rev. 2020;34(1). https://doi.org/10.1128/cmrr.00141-20.

20. Cek M, Lenik S, Naber KG, Bishop MC, Johansen TE, Botto H, et al. EAU guidelines for the management of genitourinary tuberculosis. Eur Urol. 2005;48(3):353–62. https://doi.org/10.1016/j.eururo.2005.03.008.

21. Abraham S, Izaguirre Anariba DE, Dua K, Mir M, Ankredypalli A. A case of testicular tuberculosis mimicking malignancy in a healthy young man. Ther Adv Infect Dis. 2016;3(3–4):110–3. https://doi.org/10.1177/204936116655261.

22. Ravikanth R, Kamalasekar K, Patel N. Extensive primary male genital tuberculosis. J Human Reprod Sci. 2019;12(3):258–61. https://doi.org/10.7759/cureus.2019.36116655261.

23. Ravikanth R, Kamalasekar K, Patel N. Extensive primary male genital tuberculosis. J Human Reprod Sci. 2019;12(3):258–61. https://doi.org/10.7759/cureus.2019.36116655261.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.